Orexigen Therapeutics, Inc. recalls Contrave (naltrexone HCl and bupropion HCl) Extended-Release Tablets, 8 mg/90 mg, 120-count bottle, Rx only, Distribute…
- Recall date
- August 9, 2018
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Recall number
- D-1099-2018
- FDA classification
- Class III
- Brand / firm
- Orexigen Therapeutics, Inc.
- Sold / distributed
- Nationwide in the USA
Why it was recalled
Defective Container: Customer complaints of punctures in the bottle.
Class III means the product violates regulations but is not likely to cause harm.
What was recalled
Contrave (naltrexone HCl and bupropion HCl) Extended-Release Tablets, 8 mg/90 mg, 120-count bottle, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99.
Get recall alerts
Free email alert whenever Orexigen Therapeutics, Inc. has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Orexigen Therapeutics, Inc.